Skip to main content
SpringerLink
Log in

Drugs That Affect Male Sexual Function

  • Chapter
Male Sexual Function

Part of the book series: Current Clinical Urology ((CCU))

Abstract

Many drugs are known to alter normal male sexual function. In most instances, this is an undesirable effect and every effort is made to minimize the sexual adverse effects of therapeutic pharmacological agents. The effort to use medications that have minimal risk for disruption of sexual function is complicated by the development and introduction of multiple medications for chronic vascular and neurological disease. Patient compliance can be problematic when a therapeutic agent interferes with sexual function and serious complications have been seen when patients discontinue their medications because, in their minds, the medications are interfering with their sexuality. This chapter attempts to enhance the practioners knowledge of the sexual adverse effects associated with multiple classes of therapeutic agents commonly used in medicine today.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54.

    PubMed  CAS  Google Scholar 

  2. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 2000; 163: 460–463.

    Article  PubMed  CAS  Google Scholar 

  3. National Center for Health Statistics. Health, United States with Chartbook on Trends in the Health of Americans, 2004.

    Google Scholar 

  4. Dusing R. Adverse events, compliance, and changes in therapy. Curr Hypertens Rep 2001; 3: 488–492.

    Article  PubMed  CAS  Google Scholar 

  5. Dusing R, Lottermoser K, Mengden T. Compliance with drug therapy-new answers to an old question. Nephrol Dial Transplant 2001; 16: 1317–1321.

    Article  PubMed  CAS  Google Scholar 

  6. Lue TF. Physiology of penile erectile dysfunction and priapism. In: Walsh PC, ed. Campbell’s Urology, 8th ed. W.B. Saunders Company, New York1998; 1591–1613.

    Google Scholar 

  7. Crenshaw TL, Goldberg JP. Sexual Pharmacology, First ed. W.W. Norton & Company, New York, 1996, 596.

    Google Scholar 

  8. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290: 199–206.

    Article  PubMed  Google Scholar 

  9. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206.

    Article  PubMed  CAS  Google Scholar 

  10. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med 2003; 139: 161–168.

    PubMed  Google Scholar 

  11. Oster JR, Epstein M. Use of centrally acting sympatholytic agents in the management of hypertension. Arch Intern Med 1991; 151: 1638–1644.

    Article  PubMed  CAS  Google Scholar 

  12. Sibai BM. Treatment of hypertension in pregnant women. N Engl J Med 1996; 335: 257–265.

    Article  PubMed  CAS  Google Scholar 

  13. Bansal S. Sexual dysfunction in hypertensive men. A critical review of the literature. Hypertension 1988; 12: 1–10.

    PubMed  CAS  Google Scholar 

  14. Bulpitt CJ, Dollery CT. Side effects of hypotensive agents evaluated by a self-administered questionnaire. Br Med J 1973; 3: 485–490.

    PubMed  CAS  Google Scholar 

  15. Croog SH, Levine S, Sudilovsky A, Baume RM, Clive J. Sexual symptoms in hypertensive patients. A clinical trial of antihypertensive medications. Arch Intern Med 1988; 148: 788–794.

    Article  PubMed  CAS  Google Scholar 

  16. Kolodny R. Effects of alpha-methyldopa on male sexual function. Sexual Disability 1987; 1: 223–227.

    Article  Google Scholar 

  17. Methyldopa monograph. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  18. Bauer GE, Hull RD, Stokes GS, Raftos J. The reversibility of side effects of guanethidine therapy. Med J Aust 1973; 1: 930–933.

    PubMed  CAS  Google Scholar 

  19. Laver MC. Sexual behaviour patterns in male hypertensives. Aust N Z J Med 1974; 4: 29–31.

    PubMed  CAS  Google Scholar 

  20. Guanethidine monograph. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  21. Segraves RT, Madson R, Carter CS, et al. Erectile dysfunction associated with pharmacological agents. In: Segraves RT, Schoenberg HN, eds. Diagnosis and Treatment of Erectile Disturbances. Plenum, New York; 1985; 23–63.

    Google Scholar 

  22. Reserpine monograph. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  23. Clonidine monograph. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  24. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328: 914–921.

    Article  PubMed  CAS  Google Scholar 

  25. Clonidine (Catapres) and other drugs causing sexual dysfunction. Med Lett Drugs Ther 1977; 19: 81–82.

    Google Scholar 

  26. Hogan MJ, Wallin JD, Baer RM. Antihypertensive therapy and male sexual dysfunction. Psychosomatics 1981; 21: 234–237.

    Google Scholar 

  27. Mills LC. Drug-induced impotence. Am Fam Physician 1975; 12: 104–106.

    PubMed  CAS  Google Scholar 

  28. Saunders E, Kong WB. Sexual activity in male hypertensive patients while taking clonidine. Urban Health 1980; 9: 26–34.

    Google Scholar 

  29. Burris JF, Mroczek WJ. Transdermal administration of clonidine: a new approach to antihypertensive therapy. Pharmacotherapy 1986; 6: 30–44.

    PubMed  CAS  Google Scholar 

  30. Buffum J. Pharmacosexology: the effects of drugs on sexual function a review. J Psychoactive Drugs 1982; 14: 5–44.

    PubMed  CAS  Google Scholar 

  31. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet 1981; 2: 539–543.

    Google Scholar 

  32. Bauer GE, Baker J, Hunyor SN, Marshall P. Side-effects of antihypertensive treatment: a placebocontrolled study. Clin Sci Mol Med Suppl 1978; 4: 341s–344s.

    PubMed  CAS  Google Scholar 

  33. Boyden TW, Nugent CA, Ogihara T, Maeda T. Reserpine, hydrochlorothiazide and pituitary-gonadal hormones in hypertensive patients. Eur J Clin Pharmacol 1980; 17: 329–332.

    Article  PubMed  CAS  Google Scholar 

  34. Suzuki H, Tominaga T, Kumagai H, Saruta T. Effects of first-line antihypertensive agents on sexual function and sex hormones. J Hypertens Suppl 1988; 6: S649–S651.

    Article  PubMed  CAS  Google Scholar 

  35. Chang SW, Fine R, Siegel D, Chesney M, Black D, Hulley SB. The impact of diuretic therapy on reported sexual function. Arch Intern Med 1991; 151: 2402–2408.

    Article  PubMed  CAS  Google Scholar 

  36. Ogihara T, Kuramoto K. Effect of long-term treatment with antihypertensive drugs on quality of life of elderly patients with hypertension: a double-blind comparative study between a calcium antagonist and a diuretic. NICS-EH Study Group. National Intervention Cooperative Study in Elderly Hypertensives. Hypertens Res 2000; 23: 33–37.

    PubMed  CAS  Google Scholar 

  37. Chlorthalidone monograph. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  38. Grimm RH Jr, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29: 8–14.

    PubMed  CAS  Google Scholar 

  39. Wassertheil-Smoller S, Blaufox MD, Oberman A, et al. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann Intern Med 1991; 114: 613–620.

    PubMed  CAS  Google Scholar 

  40. Fletcher A. Quality of life in the management of hypertension. Clin Exp Hypertens 1999; 21: 961–972.

    Article  PubMed  CAS  Google Scholar 

  41. Geissler AH, Turnlund JR, Cohen RD. Effect of chlorthalidone on zinc levels, testosterone, and sexual function in man. Drug Nutr Interact 1986; 4: 275–283.

    PubMed  CAS  Google Scholar 

  42. Acetazolamide monograph. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  43. Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects. Serum chemical analysis. Arch Ophthalmol 1977; 95: 1378–1382.

    PubMed  CAS  Google Scholar 

  44. Epstein RJ, Allen RC, Lunde MW. Organic impotence associated with carbonic anhydrase inhibitor therapy for glaucoma. Ann Ophthalmol 1987; 19: 48–50.

    PubMed  CAS  Google Scholar 

  45. Lacourciere Y. Analysis of well-being and 24-hour blood pressure recording in a comparative study between indapamide and captopril. Am J Med 1988; 84: 47–52.

    PubMed  CAS  Google Scholar 

  46. Werning C, Weitz T, Ludwig B. Assessment of indapamide in elderly hypertensive patients with special emphasis on well-being. Am J Med 1988; 84: 104–108.

    PubMed  CAS  Google Scholar 

  47. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–717.

    Article  PubMed  CAS  Google Scholar 

  48. Greenblatt DJ, Koch-Weser J. Gynecomastia and impotence: complications of spironolactone therapy. JAMA 1973; 223: 82.

    Article  PubMed  CAS  Google Scholar 

  49. Stevenson JG, Umstead GS. Sexual dysfunction due to antihypertensive agents. Drug Intell Clin Pharm 1984; 18: 113–121.

    PubMed  CAS  Google Scholar 

  50. Rose LI, Underwood RH, Newmark SR, Kisch ES, Williams GH. Pathophysiology of spironolactoneinduced gynecomastia. Ann Intern Med 1977; 87: 398–403.

    PubMed  CAS  Google Scholar 

  51. de Gasparo M, Whitebread SE, Preiswerk G, Jeunemaitre X, Corvol P, Menard J. Antialdosterones: incidence and prevention of sexual side effects. J Steroid Biochem 1989; 32: 223–227.

    Article  PubMed  Google Scholar 

  52. Reyes AJ, Leary WP, Crippa G, Maranhao MF, Hernandez-Hernandez R. The aldosterone antagonist and facultative diuretic eplerenone: a critical review. Eur J Intern Med 2005; 16: 3–11.

    Article  PubMed  CAS  Google Scholar 

  53. Williams GH, Burgess E, Kolloch RE, et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004; 93: 990–996.

    Article  PubMed  CAS  Google Scholar 

  54. Wagner G, Saenz de Tejada I. Update on male erectile dysfunction. BMJ 1998; 316: 678–682.

    PubMed  CAS  Google Scholar 

  55. Bulpitt CJ, Beevers DG, Butler A, et al. The effects of anti-hypertensive drugs on sexual function in men and women: a report from the DHSS Hypertension Care Computing Project (DHCCP). J Hum Hypertens 1989; 3: 53–56.

    PubMed  CAS  Google Scholar 

  56. Beta-blockers overview. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  57. al Khaja KA, Sequeira RP, al Damanhori AH, Mathur VS. Antihypertensive drug-associated sexual dysfunction: a prescription analysis-based study. Pharmacoepidemiol Drug Saf 2003; 12: 203–212.

    Article  PubMed  Google Scholar 

  58. Rosen RC, Kostis JB, Jekelis AW. Beta-blocker effects on sexual function in normal males. Arch Sex Behav 1988; 17: 241–285.

    Article  PubMed  CAS  Google Scholar 

  59. Fogari R, Preti P, Derosa G, et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 2002; 58: 177–180.

    Article  PubMed  CAS  Google Scholar 

  60. Fogari R, Zoppi A, Corradi L, Mugellini A, Poletti L, Lusardi P. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Am J Hypertens 1998; 11: 1244–1247.

    Article  PubMed  CAS  Google Scholar 

  61. Broekman CP, Haensel SM, Van de Ven LL, Slob AK. Bisoprolol and hypertension: effects on sexual functioning in men. J Sex Marital Ther 1992; 18: 325–331.

    PubMed  CAS  Google Scholar 

  62. Franzen D, Metha A, Seifert N, Braun M, Hopp HW. Effects of beta-blockers on sexual performance in men with coronary heart disease. A prospective, randomized and double blinded study. Int J Impot Res 2001; 13: 348–351.

    Article  PubMed  CAS  Google Scholar 

  63. Hollifield JW, Sherman K, Zwagg RV, Shand DG. Proposed mechanisms of propranolol’s antihypertensive effect in essential hypertension. N Engl J Med 1976; 295: 68–73.

    Article  PubMed  CAS  Google Scholar 

  64. Forsberg L, Gustavii B, Hojerback T, Olsson AM. Impotence, smoking, and beta-blocking drugs. Fertil Steril 1979; 31: 589–591.

    PubMed  CAS  Google Scholar 

  65. Miller RA. Propranolol and impotence. Ann Intern Med 1976; 85: 682–683.

    PubMed  CAS  Google Scholar 

  66. Flamenbaum W, Weber MA, McMahon FG, Materson BJ, Carr AA, Poland M. Monotherapy with labetalol compared with propranolol. Differential effects by race. J Clin Hypertens 1985; 1: 56–69.

    PubMed  CAS  Google Scholar 

  67. Michelson EL, Frishman WH, Lewis JE, et al. Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension. Am J Med 1983; 75: 68–80.

    Article  PubMed  CAS  Google Scholar 

  68. Patten SB. Propranolol and depression: evidence from the antihypertensive trials. Can J Psychiatry 1990; 35: 257–259.

    PubMed  CAS  Google Scholar 

  69. Avorn J, Everitt DE, Weiss S. Increased antidepressant use in patients prescribed beta-blockers. JAMA 1986; 255: 357–360.

    Article  PubMed  CAS  Google Scholar 

  70. Silvestri A, Galetta P, Cerquetani E, et al. Report of erectile dysfunction after therapy with betablockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J 2003; 24: 1928–1932.

    Article  PubMed  CAS  Google Scholar 

  71. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283: 1967–1975.

    Article  Google Scholar 

  72. Pitts NE. The clinical evaluation of prazosin: Excerpta Medica Amsterdam, 1974, 68–73.

    Google Scholar 

  73. Burke JR, Hirst G. Priapism and prazosin. Med J Aust 1980; 1: 382–383.

    PubMed  CAS  Google Scholar 

  74. Robbins DN, Crawford ED, Lackner LH. Priapism secondary to prazosin overdose. J Urol 1983; 130: 975.

    PubMed  CAS  Google Scholar 

  75. Carbone DJ Jr, Hodges S. Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life. Int J Impot Res 2003; 15: 299–306.

    Article  PubMed  Google Scholar 

  76. Narayan P, Lepor H. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 2001; 57: 466–470.

    Article  PubMed  CAS  Google Scholar 

  77. Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol 1998; 160: 1701–1706.

    Article  PubMed  CAS  Google Scholar 

  78. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998; 51: 901–906.

    Article  PubMed  CAS  Google Scholar 

  79. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998; 51: 892–900.

    Article  PubMed  CAS  Google Scholar 

  80. Giuliano F, Bernabe J, Droupy S, Alexandre L, Allard J. A comparison of the effects of tamsulosin and alfuzosin on neurally evoked increases in bladder neck and seminal vesicle pressure in rats. BJU Int 2004; 93: 605–608.

    Article  PubMed  CAS  Google Scholar 

  81. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003; 92: 257–261.

    Article  PubMed  CAS  Google Scholar 

  82. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170: 530–547.

    Article  Google Scholar 

  83. Dodds PR, Batter SJ, Serels SR. Priapism following ingestion of tamsulosin. J Urol 2003; 169: 2302.

    Article  PubMed  Google Scholar 

  84. Omvik P, Thaulow E, Herland OB, Eide I, Midha R, Turner RR. Double-blind, parallel, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicentre study. J Hypertens 1993; 11: 103–113.

    Article  PubMed  CAS  Google Scholar 

  85. Kroner BA, Mulligan T, Briggs GC. Effect of frequently prescribed cardiovascular medications on sexual function: a pilot study. Ann Pharmacother 1993; 27: 1329–1332.

    PubMed  CAS  Google Scholar 

  86. Clone CA. Unilateral gynecomastia and nifedipine. Br Med J 1986; 380.

    Google Scholar 

  87. Tanner LA, Bosco LA. Gynecomastia associated with calcium channel blocker therapy. Arch Intern Med 1988; 148: 379–380.

    Article  PubMed  CAS  Google Scholar 

  88. ACE inhibitor reduced heart failure deaths in SOLVD. Br J Hosp Med 1991; 46: 345.

    Google Scholar 

  89. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325: 293–302.

    Article  Google Scholar 

  90. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657–1664.

    Article  PubMed  CAS  Google Scholar 

  91. Warner NJ, Rush JE. Safety profiles of the angiotensin-converting enzyme inhibitors. Drugs 1988; 35(Suppl 5): 89–97.

    PubMed  Google Scholar 

  92. Frcka G, Lader M. Psychotropic effects of repeated doses of enalapril, propranolol and atenolol in normal subjects. Br J Clin Pharmacol 1988; 25: 67–73.

    PubMed  CAS  Google Scholar 

  93. Losartan monograph. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  94. Llisterri JL, Lozano Vidal JV, Aznar Vicente J, et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001; 321: 336–341.

    Article  PubMed  CAS  Google Scholar 

  95. Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001; 14: 27–31.

    Article  PubMed  CAS  Google Scholar 

  96. Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl 2003; 2: 29–34.

    Article  PubMed  CAS  Google Scholar 

  97. Ferrario CM, Levy P. Sexual dysfunction in patients with hypertension: implications for therapy. J Clin Hypertens (Greenwich) 2002; 4: 424–432.

    Google Scholar 

  98. Casper RC, Redmond DE Jr, Katz MM, Schaffer CB, Davis JM, Koslow SH. Somatic symptoms in primary affective disorder. Presence and relationship to the classification of depression. Arch Gen Psychiatry 1985; 42: 1098–1104.

    PubMed  CAS  Google Scholar 

  99. Rosen RC, Marin H. Prevalence of antidepressant-associated erectile dysfunction. J Clin Psychiatry 2003; 64(Suppl 10): 5–10.

    PubMed  Google Scholar 

  100. Rudkin L, Taylor MJ, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev: 2004; CD003382.

    Google Scholar 

  101. Tricyclic antidepressants overview. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  102. Nofzinger EA, Thase ME, Reynolds CF 3rd, et al. Sexual function in depressed men. Assessment by self-report, behavioral, and nocturnal penile tumescence measures before and after treatment with cognitive behavior therapy. Arch Gen Psychiatry 1993; 50: 24–30.

    PubMed  CAS  Google Scholar 

  103. DeVeaugh-Geiss J, Landau P, Katz R. Preliminary results from a multicenter trial of clomipramine in obsessive-compulsive disorder. Psychopharmacol Bull 1989; 25: 36–40.

    PubMed  CAS  Google Scholar 

  104. Harrison WM, Rabkin JG, Ehrhardt AA, et al. Effects of antidepressant medication on sexual function: a controlled study. J Clin Psychopharmacol 1986; 6: 144–149.

    Article  PubMed  CAS  Google Scholar 

  105. Balon R, Yeragani VK, Pohl R, Ramesh C. Sexual dysfunction during antidepressant treatment. J Clin Psychiatry 1993; 54: 209–212.

    PubMed  CAS  Google Scholar 

  106. Mitchell JE, Popkin MK. Antidepressant drug therapy and sexual dysfunction in men: a review. J Clin Psychopharmacol 1983; 3: 76–79.

    Article  PubMed  CAS  Google Scholar 

  107. Yager J. Bethanechol chloride can reverse erectile and ejaculatory dysfunction induced by tricyclic antidepressants and mazindol: case report. J Clin Psychiatry 1986; 47: 210–211.

    PubMed  CAS  Google Scholar 

  108. Glass RM. Ejaculatory impairment from both phenelzine and imipramine, with tinnitus from phenelzine. J Clin Psychopharmacol 1981; 1: 152–154.

    PubMed  CAS  Google Scholar 

  109. Rosenbaum JF, Pollack MH. Anhedonic ejaculation with desipramine. Int J Psychiatry Med 1988; 18: 85–88.

    Article  PubMed  CAS  Google Scholar 

  110. Hekimian LJ, Friedhoff AJ, Deever E. A comparison of the onset of action and therapeutic efficacy of amoxapine and amitriptyline. J Clin Psychiatry 1978; 39: 633–637.

    PubMed  CAS  Google Scholar 

  111. Greenberg HR. Erectile impotence during the course of tofranil therapy. Am J Psychiatry 1965; 121: 1021.

    PubMed  CAS  Google Scholar 

  112. Segraves RT. Reversal of bethanechol of imipramine-induced ejaculatory dysfunction. Am J Psychiatry 1986; 1243–1244.

    Google Scholar 

  113. Riley AJ, Riley EJ. Cyproheptadine and antidepressant-induced anorgasmia. Br J Psychiatry 1986; 148: 217–218.

    PubMed  CAS  Google Scholar 

  114. Monoamine oxidase inhibitors overview. In: Clinical Pharmacology: Gold Standard 2005.

    Google Scholar 

  115. Bochinski D, Brock GB. Medications affecting erectile function. In: Mulcahy JJ, ed. Male Sexual Function: A Guide to Clinical Management, First ed. Humana Press, Totowa, New Jersey, 2001, 91–108.

    Google Scholar 

  116. Remick RA, Froese C, Keller FD. Common side effects associated with monoamine oxidase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13: 497–504.

    Article  PubMed  CAS  Google Scholar 

  117. Harrison WM, Stewart J, Ehrhardt AA, et al. A controlled study of the effects of antidepressants on sexual function. Psychopharmacol Bull 1985; 21: 85–88.

    PubMed  CAS  Google Scholar 

  118. Buigues J, Vallejo J. Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. J Clin Psychiatry 1987; 48: 55–59.

    PubMed  CAS  Google Scholar 

  119. Barton JL. Orgasmic inhibition by phenelzine. Am J Psychiatry 1979; 136: 1616–1617.

    PubMed  CAS  Google Scholar 

  120. Rapp MS. Two cases of ejaculatory impairment related to phenelzine. Am J Psychiatry 1979; 136: 1200–1201.

    PubMed  CAS  Google Scholar 

  121. Yeragani VK, Gershon S. Priapism related to phenelzine therapy. N Engl J Med 1987; 317: 117–118.

    PubMed  CAS  Google Scholar 

  122. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 1992; 161: 353–360.

    PubMed  CAS  Google Scholar 

  123. Phillip M, Kohnen R, Benkert O. Comparison study of moclobemide and doxepine with special reference to the effects on sexual dysfunction. Neuropsychoparmacology 1994; 845.

    Google Scholar 

  124. Selective serotonin reuptake inhibitors overview. In: Clinical Pharmacology: Gold Standard 2005.

    Google Scholar 

  125. Herman JB, Brotman AW, Pollack MH, Falk WE, Biederman J, Rosenbaum JF. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 1990; 51: 25–27.

    PubMed  CAS  Google Scholar 

  126. Musher JS. Anorgasmia with the use of fluoxetine. Am J Psychiatry 1990; 147: 948.

    PubMed  CAS  Google Scholar 

  127. Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992; 53: 119–122.

    PubMed  CAS  Google Scholar 

  128. Patterson WM. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 1993; 54: 71.

    PubMed  CAS  Google Scholar 

  129. Neill JR. Penile anesthesia associated with fluoxetine use. Am J Psychiatry 1991; 148: 1603.

    PubMed  CAS  Google Scholar 

  130. Measom MO. Penile anesthesia and fluoxetine. Am J Psychiatry 1992; 149: 709.

    PubMed  CAS  Google Scholar 

  131. Doogan DP, Caillard V. Sertraline: a new antidepressant. J Clin Psychiatry 1988; 49(Suppl): 46–51.

    PubMed  Google Scholar 

  132. Reimherr FW, Chouinard G, Cohn CK, et al. Antidepressant efficacy of sertraline: a double-blind, placebo-and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990; 51(Suppl B): 18–27.

    PubMed  Google Scholar 

  133. Cohn CK, Shrivastava R, Mendels J, et al. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990; 51(Suppl B): 28–33.

    PubMed  Google Scholar 

  134. Ekselius L, von Knorring L. Effect on sexual function of long-term treatment with selective serotonin reuptake inhibitors in depressed patients treated in primary care. J Clin Psychopharmacol 2001; 21: 154–160.

    Article  PubMed  CAS  Google Scholar 

  135. Peselow ED, Filippi AM, Goodnick P, Barouche F, Fieve RR. The short-and long-term efficacy of paroxetine HCl: A. Data from a 6-week double-blind parallel design trial vs imipramine and placebo. Psychopharmacol Bull 1989; 25: 267–271.

    PubMed  CAS  Google Scholar 

  136. Claghorn J. A double-blind comparison of paroxetine and placebo in the treatment of depressed outpatients. Int Clin Psychopharmacol 1992; 6(Suppl 4): 25–30.

    PubMed  Google Scholar 

  137. Dechant KL, Clissold SP. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991; 41: 225–253.

    PubMed  CAS  Google Scholar 

  138. Grimsley SR, Jann MW. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 1992; 11: 930–957.

    PubMed  CAS  Google Scholar 

  139. Schweizer E, Feighner J, Mandos LA, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994; 55: 104–108.

    PubMed  CAS  Google Scholar 

  140. Ashton AK, Hamer R, Rosen RC. Serotonin reuptake inhibitor induced sexual dysfunction and its treatment: a large scale retrospective study of 596 psychiatric outpatients. J Sex Marital Ther 1997; 165–175.

    Google Scholar 

  141. Aizenberg D, Weizman A, Barak Y. Sildenafil for selective serotonin reuptake inhibitor-induced erectile dysfunction in elderly male depressed patients. J Sex Marital Ther 2003; 29: 297–303.

    Article  PubMed  Google Scholar 

  142. Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J, Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA 2003; 289: 56–64.

    Article  PubMed  CAS  Google Scholar 

  143. Cohen AJ, Bartlik B. Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Ther 1998; 24: 139–143.

    PubMed  CAS  Google Scholar 

  144. Kang BJ, Lee SJ, Kim MD, Cho MJ. A placebo-controlled, double-blind trial of Ginkgo biloba for antidepressant-induced sexual dysfunction. Hum Psychopharmacol 2002; 17: 279–284.

    Article  PubMed  Google Scholar 

  145. Waldinger MD. Lifelong premature ejaculation: from authority-based to evidence-based medicine. BJU Int 2004; 93: 201–207.

    Article  PubMed  CAS  Google Scholar 

  146. Waldinger MD, Zwinderman AH, Olivier B. On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomized, double-blind fixed-dose study with stopwatch assessment. Eur Urol 2004; 46: 510–515; discussion 516.

    PubMed  CAS  Google Scholar 

  147. Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res 2004; 16: 369–381.

    Article  PubMed  CAS  Google Scholar 

  148. Lithium monograph. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  149. Page C, Benaim S, Lappin F. A long-term retrospective follow-up study of patients treated with prophylactic lithium carbonate. Br J Psychiatry 1987; 150: 175–179.

    PubMed  CAS  Google Scholar 

  150. Ghadirian AM, Annable L, Belanger MC. Lithium, benzodiazepines, and sexual function in bipolar patients. Am J Psychiatry 1992; 149: 801–805.

    PubMed  CAS  Google Scholar 

  151. Trazodone monograph. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  152. Nefazodone monograph. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  153. Banos JE, Bosch F, Farre M. Drug-induced priapism. Its aetiology, incidence and treatment. Med Toxicol Adverse Drug Exp 1989; 4: 46–58.

    PubMed  CAS  Google Scholar 

  154. Saenz de Tejada I, Ware JC, Blanco R, et al. Pathophysiology of prolonged penile erection associated with trazodone use. J Urol 1991; 145: 60–64.

    Google Scholar 

  155. Albo M, Steers WD. Oral trazodone as initial therapy for management of impotence. J Urol 1993; 149(Suppl): 344A.

    Google Scholar 

  156. Lance R, Albo M, Costabile RA, Steers WD. Oral trazodone as empirical therapy for erectile dysfunction: a retrospective review. Urology 1995; 46: 117–120.

    Article  PubMed  CAS  Google Scholar 

  157. Costabile RA, Spevak M. Oral trazodone is not effective therapy for erectile dysfunction: a doubleblind, placebo controlled trial. J Urol 1999; 161: 1819–1822.

    Article  PubMed  CAS  Google Scholar 

  158. Sullivan G. Increased libido in three men treated with trazodone. J Clin Psychiatry 1988; 49: 202–203.

    PubMed  CAS  Google Scholar 

  159. Clayton AH, Pradko JF, Croft H, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002; 63: 357–366.

    PubMed  Google Scholar 

  160. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001; 62(Suppl 3): 10–23.

    PubMed  CAS  Google Scholar 

  161. Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996; 57(Suppl 2): 53–62.

    PubMed  CAS  Google Scholar 

  162. Ferguson JM, Shrivastava RK, Stahl SM, et al. Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline. J Clin Psychiatry 2001; 62: 24–29.

    Article  PubMed  CAS  Google Scholar 

  163. Bupropion monograph. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  164. Bryant SG, Guernsey BG, Ingrim NB. Review of bupropion. Clin Pharm 1983; 2: 525–537.

    PubMed  CAS  Google Scholar 

  165. Feighner JP, Gardner EA, Johnston JA, et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 1991; 52: 329–335.

    PubMed  CAS  Google Scholar 

  166. Crenshaw TL, Goldberg JP, Stern WC. Pharmacologic modification of psychosexual dysfunction. J Sex Marital Ther 1987; 13: 239–252.

    PubMed  CAS  Google Scholar 

  167. Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry 1993; 54: 459–465.

    PubMed  CAS  Google Scholar 

  168. Masand PS, Ashton AK, Gupta S, Frank B. Sustained-release bupropion for selective serotonin reuptake inhibitor-induced sexual dysfunction: a randomized, double-blind, placebo-controlled, parallelgroup study. Am J Psychiatry 2001; 158: 805–807.

    Article  PubMed  CAS  Google Scholar 

  169. Barkin RL, Chor PN, Braun BG, Schwer WA. A Trilogy Case Review Highlighting the Clinical and Pharmacologic Applications of Mirtazapine in Reducing Polypharmacy for Anxiety, Agitation, Insomnia, Depression, and Sexual Dysfunction. Prim Care Companion J Clin Psychiatry 1999; 1: 142–145.

    PubMed  Google Scholar 

  170. Stimmel GL, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997; 17: 10–21.

    PubMed  CAS  Google Scholar 

  171. Gelenberg AJ, McGahuey C, Laukes C, et al. Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry 2000; 61: 356–360.

    Article  PubMed  CAS  Google Scholar 

  172. Koutouvidis N, Pratikakis M, Fotiadou A. The use of mirtazapine in a group of 11 patients following poor compliance to selective serotonin reuptake inhibitor treatment due to sexual dysfunction. Int Clin Psychopharmacol 1999; 14: 253–255.

    Article  PubMed  CAS  Google Scholar 

  173. Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. Ann Pharmacother 2002; 36: 1577–1589.

    Article  PubMed  CAS  Google Scholar 

  174. Boyarsky BK, Haque W, Rouleau MR, Hirschfeld RM. Sexual functioning in depressed outpatients taking mirtazapine. Depress Anxiety 1999; 9: 175–179.

    Article  PubMed  CAS  Google Scholar 

  175. Macdonald S, Halliday J, Mac ET, et al. Nithsdale Schizophrenia Surveys 24: sexual dysfunction. Case-control study. Br J Psychiatry 2003; 182: 50–56.

    Article  PubMed  CAS  Google Scholar 

  176. Cutler AJ. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 2003; 28(Suppl 1): 69–82.

    Article  PubMed  CAS  Google Scholar 

  177. Dossenbach M, Hodge A, Anders M, et al. Prevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimation. Int J Neuropsychopharmacol 2005; 8: 195–201.

    Article  PubMed  Google Scholar 

  178. Lambert M, Conus P, Eide P, et al. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 2004; 19: 415–422.

    Article  PubMed  CAS  Google Scholar 

  179. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64: 2291–2314.

    Article  PubMed  CAS  Google Scholar 

  180. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002; 63: 1121–1128.

    PubMed  Google Scholar 

  181. Antipsychotics overview. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  182. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1–100.

    Article  PubMed  CAS  Google Scholar 

  183. Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 1999; 35(Suppl): S67–S73.

    Article  PubMed  Google Scholar 

  184. Kotin J, Wilbert DE, Verburg D, Soldinger SM. Thioridazine and sexual dysfunction. Am J Psychiatry 1976; 133: 82–85.

    PubMed  CAS  Google Scholar 

  185. Laughren TP, Brown WA, Petrucci JA. Effects of thioridazine on serum testosterone. Am J Psychiatry 1978; 135: 982–984.

    PubMed  CAS  Google Scholar 

  186. Drugs that cause sexual dysfunction. Med Lett Drugs Ther 1987; 29: 65–70.

    Google Scholar 

  187. Brock GB, Lue TF. Drug-induced male sexual dysfunction. An update. Drug Saf 1993; 8: 414–426.

    CAS  Google Scholar 

  188. Ahl J, Kinon BJ, Liu-Seifert H. Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels. Ann NY Acad Sci 2004; 1032: 289–290.

    Article  PubMed  Google Scholar 

  189. Byerly MJ, Lescouflair E, Weber MT, et al. An open-label trial of quetiapine for antipsychoticinduced sexual dysfunction. J Sex Marital Ther 2004; 30: 325–332.

    Article  PubMed  Google Scholar 

  190. Knegtering R, Castelein S, Bous H, et al. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol 2004; 24: 56–61.

    Article  PubMed  CAS  Google Scholar 

  191. Aizenberg D, Modai I, Landa A, Gil-Ad I, Weizman A. Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. J Clin Psychiatry 2001; 62: 541–544.

    Article  PubMed  CAS  Google Scholar 

  192. Wirshing DA, Pierre JM, Marder SR, Saunders CS, Wirshing WC. Sexual side effects of novel antipsychotic medications. Schizophr Res 2002; 56: 25–30.

    Article  PubMed  Google Scholar 

  193. Loh C, Leckband SG, Meyer JM, Turner E. Risperidone-induced retrograde ejaculation: case report and review of the literature. Int Clin Psychopharmacol 2004; 19: 111–112.

    Article  PubMed  Google Scholar 

  194. Holtmann M, Gerstner S, Schmidt MH. Risperidone-associated ejaculatory and urinary dysfunction in male adolescents. J Child Adolesc Psychopharmacol 2003; 13: 107–109.

    Article  PubMed  Google Scholar 

  195. Compton MT, Miller AH. Priapism associated with conventional and atypical antipsychotic medications: a review. J Clin Psychiatry 2001; 62: 362–366.

    Article  PubMed  CAS  Google Scholar 

  196. Songer DA, Barclay JC. Olanzapine-induced priapism. Am J Psychiatry 2001; 158: 2087–2088.

    Article  PubMed  CAS  Google Scholar 

  197. Valevski A, Modai I, Zbarski E, Zemishlany Z, Weizman A. Effect of amantadine on sexual dysfunction in neuroleptic-treated male schizophrenic patients. Clin Neuropharmacol 1998; 21: 355–357.

    PubMed  CAS  Google Scholar 

  198. Aviv A, Shelef A, Weizman A. An open-label trial of sildenafil addition in risperidone-treated male schizophrenia patients with erectile dysfunction. J Clin Psychiatry 2004; 65: 97–103.

    Article  PubMed  CAS  Google Scholar 

  199. Atmaca M, Kuloglu M, Tezcan E. Sildenafil use in patients with olanzapine-induced erectile dysfunction. Int J Impot Res 2002; 14: 547–549.

    Article  PubMed  CAS  Google Scholar 

  200. Salerian AJ, Deibler WE, Vittone BJ, et al. Sildenafil for psychotropic-induced sexual dysfunction in 31 women and 61 men. J Sex Marital Ther 2000; 26: 133–140.

    Article  PubMed  CAS  Google Scholar 

  201. Benzodiazepines overview. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  202. Magnus RV, Dean BC, Curry SH. Clorazepate: double blind crossover comparison of a single nightly dose with diazepam thrice daily in anxiety. Dis Nerv Syst 1977; 38: 819–821.

    PubMed  CAS  Google Scholar 

  203. Balon R, Ramesh C, Pohl R. Sexual dysfunction associated with diazepam but not with clonazepam. Can J Psychiatry 1989; 34: 947–948.

    PubMed  CAS  Google Scholar 

  204. Khandelwal SK. Complete loss of libido with short-term use of lorazepam. Am J Psychiatry 1988; 145: 1313–1314.

    PubMed  CAS  Google Scholar 

  205. Uhde TW, Tancer ME, Shea CA. Sexual dysfunction related to alprazolam treatment of social phobia. 1988; Am J Psychiatry 145: 531–532.

    Google Scholar 

  206. Segraves RT. Sexual side-effects of psychiatric drugs. Int J Psychiatry Med 1988; 18: 243–252.

    Article  PubMed  CAS  Google Scholar 

  207. Jenner P, Marsden CD, Pratt J, Reynolds EH. Altered serotoninergic activity in mouse brain induced by clonazepam [proceedings]. Br J Pharmacol 1978; 64: 432P.

    PubMed  CAS  Google Scholar 

  208. Anglin D, Spears KL, Hutson HR. Flunitrazepam and its involvement in date or acquaintance rape. Acad Emerg Med 1997; 4: 323–326.

    PubMed  CAS  Google Scholar 

  209. Smith KM. Drugs used in acquaintance rape. J Am Pharm Assoc (Wash) 1999; 39: 519–525; quiz 581-613.

    CAS  Google Scholar 

  210. Fava M, Borofsky GF. Sexual disinhibition during treatment with a benzodiazepine: a case report. Int J Psychiatry Med 1991; 21: 99–104.

    Article  PubMed  CAS  Google Scholar 

  211. Gifford LM, Aeugle ME, Myerson RM, Tannenbaum PJ. Cimetidine postmarket outpatient surveillance program. Interim report on phase I. JAMA 1980; 243: 1532–1535.

    Article  PubMed  CAS  Google Scholar 

  212. Peden NR, Cargill JM, Browning MC, Saunders JH, Wormsley KG. Male sexual dysfunction during treatment with cimetidine. Br Med J 1979; 1: 659.

    PubMed  CAS  Google Scholar 

  213. Wolfe MM. Impotence on cimetidine treatment. N Engl J Med 1979; 300: 94.

    PubMed  CAS  Google Scholar 

  214. Knigge U, Matzen S, Warberg J. Histaminergic stimulation of prolactin secretion mediated via H1-or H2-receptors: dependence on routes of administration. Neuroendocrinology 1986; 44: 41–48.

    PubMed  CAS  Google Scholar 

  215. Galbraith RA, Michnovicz JJ. The effects of cimetidine on the oxidative metabolism of estradiol. N Engl J Med 1989; 321: 269–274.

    Article  PubMed  CAS  Google Scholar 

  216. Humphries TJ, Myerson RM, Gifford LM, et al. A unique postmarket outpatient surveillance program of cimetidine: report on phase II and final summary. Am J Gastroenterol 1984; 79: 593–596.

    PubMed  CAS  Google Scholar 

  217. Jensen RT, Collen MJ, Pandol SJ, et al. Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states. N Engl J Med 1983; 308: 883–887.

    Article  PubMed  CAS  Google Scholar 

  218. Van Thiel DH, Gavaler JS, Smith WI Jr, Paul G. Hypothalamic-pituitary-gonadal dysfunction in men using cimetidine. N Engl J Med 1979; 300: 1012–1015.

    Article  PubMed  Google Scholar 

  219. Van Thiel DH, Gavaler JS, Heyl A, Susen B. An evaluation of the anti-androgen effects associated with H2 antagonist therapy. Scand J Gastroenterol Suppl 1987; 136: 24–28.

    PubMed  Google Scholar 

  220. Paulsen CA, Enzmann GD, Bremner WJ, Perrin EB, Rogers BJ. Effects of cimetidine in reproductive function in men. Postgrad Med J 1983; 56: 478–480.

    Google Scholar 

  221. H2 blockers overview. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  222. Lindquist M, Edwards IR. Endocrine adverse effects of omeprazole. BMJ 1992; 305: 451–452.

    PubMed  CAS  Google Scholar 

  223. Digoxin monograph. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  224. LeWinn EB. The steroidal actions of digitalis. Perspect Biol Med 1984; 27: 183–199.

    PubMed  CAS  Google Scholar 

  225. Nielsen BB. Fibroadenomatoid hyperplasia of the male breast. Am J Surg Pathol 1990; 14: 774–777.

    Article  PubMed  CAS  Google Scholar 

  226. Neri A, Aygen M, Zukerman Z, Bahary C. Subjective assessment of sexual dysfunction of patients on long-term administration of digoxin. Arch Sex Behav 1980; 9: 343–347.

    Article  PubMed  CAS  Google Scholar 

  227. Stoffer SS, Hynes KM, Jiang NS, Ryan RJ. Digoxin and abnormal serum hormone levels. JAMA 1973; 225: 1643–1644.

    Article  PubMed  CAS  Google Scholar 

  228. Tappler B, Katz M. Pituitary-gonadal dysfunction in low-output cardiac failure. Clin Endocrinol (Oxf) 1979; 10: 219–226.

    CAS  Google Scholar 

  229. Gupta S, Salimpour P, Saenz de Tejada I, et al. A possible mechanism for alteration of human erectile function by digoxin: inhibition of corpus cavernosum sodium/potassium adenosine triphosphatase activity. J Urol 1998; 159: 1529–1536.

    Article  PubMed  CAS  Google Scholar 

  230. Antilipemics overview. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  231. Bruckert E, Giral P, Heshmati HM, Turpin G. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther 1996; 21: 89–94.

    PubMed  CAS  Google Scholar 

  232. Schneider J, Kaffarnik H. Impotence in patients treated with clofibrate. Atherosclerosis 1975; 21: 455–457.

    Article  PubMed  CAS  Google Scholar 

  233. Bain SC, Lemon M, Jones AF. Gemfibrozil-induced impotence. Lancet 1990; 336: 1389.

    Article  PubMed  CAS  Google Scholar 

  234. Pizarro S, Bargay J, D’Agosto P. Gemfibrozil-induced impotence. Lancet 1990; 336: 1135.

    Article  PubMed  CAS  Google Scholar 

  235. James CW, Wu TS, McNelis KC. Sexual dysfunction secondary to gemfibrozil. Pharmacotherapy 2002; 22: 123–125.

    Article  PubMed  Google Scholar 

  236. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360–381.

    Google Scholar 

  237. Halkin A, Lossos IS, Mevorach D. HMG-CoA reductase inhibitor-induced impotence. Ann Pharmacother 1996; 30: 192.

    PubMed  CAS  Google Scholar 

  238. Jackson G. Simvastatin and impotence. Br Med J 1997; 315: 31.

    Google Scholar 

  239. Boyd IW. Comment: HMG-CoA reductase inhibitor-induced impotence. Ann Pharmacother 1996; 30: 1199.

    PubMed  CAS  Google Scholar 

  240. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.

    Google Scholar 

  241. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349–1357.

    Google Scholar 

  242. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–1009.

    Article  PubMed  CAS  Google Scholar 

  243. Azzarito C, Boiardi L, Vergoni W, Zini M, Portioli I. Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment. Horm Metab Res 1996; 28: 193–198.

    PubMed  CAS  Google Scholar 

  244. Rossato M, Guarneri G, Lavagnini T, Padovan D, Foresta C. Simvastatin influences testicular steroidogenesis in human. Horm Metab Res 1993; 25: 503–505.

    PubMed  CAS  Google Scholar 

  245. Dobs AS, Sarma PS, Schteingart D. Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Metabolism 1993; 42: 1146–1152.

    Article  PubMed  CAS  Google Scholar 

  246. Jay RH, Sturley RH, Stirling C, et al. Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia. Br J Clin Pharmacol 1991; 32: 417–422.

    PubMed  CAS  Google Scholar 

  247. Rizvi K, Hampson JP, Harvey JN. Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract 2002; 19: 95–98.

    Google Scholar 

  248. Anticonvulsants overview. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  249. Morrell MJ. Sexual dysfunction in epilepsy. Epilepsia 1991; 32(Suppl 6): S38–S45.

    Article  PubMed  Google Scholar 

  250. Valproate monograph. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  251. Rattya J, Turkka J, Pakarinen AJ, et al. Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology 2001; 56: 31–36.

    PubMed  CAS  Google Scholar 

  252. Isojarvi JI, Pakarinen AJ, Ylipalosaari PJ, Myllyla VV. Serum hormones in male epileptic patients receiving anticonvulsant medication. Arch Neurol 1990; 47: 670–676.

    PubMed  CAS  Google Scholar 

  253. Franceschi M, Perego L, Cavagnini F, et al. Effects of long-term antiepileptic therapy on the hypothalamic-pituitary axis in man. Epilepsia 1984; 25: 46–52.

    Article  PubMed  CAS  Google Scholar 

  254. Macphee GJ, Mitchell JR, Wiseman L, et al. Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man. Br J Clin Pharmacol 1988; 25: 59–66.

    PubMed  CAS  Google Scholar 

  255. Connell JM, Rapeport WG, Beastall GH, Brodie MJ. Changes in circulating androgens during short term carbamazepine therapy. Br J Clin Pharmacol 1984; 17: 347–351.

    PubMed  CAS  Google Scholar 

  256. Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 2004; 5: 627–635.

    Article  PubMed  Google Scholar 

  257. Dana-Haeri J, Oxley J, Richens A. Reduction of free testosterone by antiepileptic drugs. Br Med J (Clin Res Ed) 1982; 284: 85–86.

    CAS  Google Scholar 

  258. Heroz AG, Levesque LA, Drislane FW, Ronthal M, Schomer DL. Phenytoin-induced elevation of serum estradiol and reproductive dysfunction in men with epilepsy. Epilepsia 1991; 32: 550–553.

    Article  PubMed  CAS  Google Scholar 

  259. Primidone monograph. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  260. Phenobarbital monograph. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  261. Mattson RH, Cramer JA. Epilepsy, sex hormones, and antiepileptic drugs. Epilepsia 1985; 26(Suppl 1): S40–S51.

    Article  PubMed  Google Scholar 

  262. Beghi E, Di Mascio R, Tognoni G. Adverse effects of anticonvulsant drugs-a critical review. Adverse Drug React Acute Poisoning Rev 1986; 5: 63–86.

    PubMed  CAS  Google Scholar 

  263. Husain AM, Carwile ST, Miller PP, Radtke RA. Improved sexual function in three men taking lamotrigine for epilepsy. South Med J 2000; 93: 335–336.

    PubMed  CAS  Google Scholar 

  264. Goserelin monograph. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  265. Marumo K, Baba S, Murai M. Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone-releasing hormone agonist therapy. Int J Urol 1999; 6: 19–23.

    Article  PubMed  CAS  Google Scholar 

  266. Briken P, Nika E, Berner W. Treatment of paraphilia with luteinizing hormone-releasing hormone agonists. J Sex Marital Ther 2001; 27: 45–55.

    Article  PubMed  CAS  Google Scholar 

  267. Pether M, Goldenberg SL, Bhagirath K, Gleave M. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience. Can J Urol 2003; 10: 1809–1814.

    PubMed  Google Scholar 

  268. Albrecht W, Collette L, Fava C, et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. Eur Urol 2003; 44: 505–511.

    Article  PubMed  CAS  Google Scholar 

  269. Testosterone monograph. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  270. Abrahamsson PA. Treatment of locally advanced prostate cancer-a new role for antiandrogen monotherapy? Eur Urol 2001; 39(Suppl 1): 22–28.

    Article  PubMed  CAS  Google Scholar 

  271. Boccardo F, Rubagotti A, Barichello M, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 1999; 17: 2027–2038.

    PubMed  CAS  Google Scholar 

  272. McLeod DG. Emerging role of adjuvant hormonal therapy. Urology 2002; 60: 13–20; discussion 21.

    Article  PubMed  Google Scholar 

  273. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215–224.

    Article  PubMed  CAS  Google Scholar 

  274. Wessells H, Roy J, Bannow J, et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 2003; 61: 579–584.

    Article  PubMed  Google Scholar 

  275. Lowe FC, McConnell JD, Hudson PB, et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 2003; 61: 791–796.

    Article  PubMed  Google Scholar 

  276. Dohle GR, Smit M, Weber RF. Androgens and male fertility. World J Urol 2003; 21: 341–345.

    Article  PubMed  CAS  Google Scholar 

  277. Urhausen A, Torsten A, Wilfried K. Reversibility of the effects on blood cells, lipids, liver function and hormones in former anabolic-androgenic steroid abusers. J Steroid Biochem Mol Biol 2003; 84: 369–375.

    Article  PubMed  CAS  Google Scholar 

  278. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med 2004; 34: 513–554.

    Article  PubMed  Google Scholar 

  279. Johnson SD, Phelps DL, Cottler LB. The association of sexual dysfunction and substance use among a community epidemiological sample. Arch Sex Behav 2004; 33: 55–63.

    Article  PubMed  Google Scholar 

  280. Wilson GT, Lawson DM. Expectancies, alcohol, and sexual arousal in male social drinkers. J Abnorm Psychol 1976; 85: 587–594.

    Article  PubMed  CAS  Google Scholar 

  281. Lemere F, Smith JW. Alcohol-induced sexual impotence. Am J Psychiatry 1973; 130: 212–213.

    PubMed  CAS  Google Scholar 

  282. Whalley LJ. Sexual adjustment of male alcoholics. Acta Psychiatr Scand 1978; 58: 281–298.

    Article  PubMed  CAS  Google Scholar 

  283. Jensen SB. Sexual function and dysfunction in younger married alcoholics. A comparative study. Acta Psychiatr Scand 1984; 69: 543–549.

    Article  PubMed  CAS  Google Scholar 

  284. Lindholm J, Fabricius-Bjerre N, Bahnsen M, et al. Pituitary-testicular function in patients with chronic alcoholism. Eur J Clin Invest 1978; 8: 269–272.

    PubMed  CAS  Google Scholar 

  285. Vijayasenan ME. Alcohol and sex. N Z Med J 1981; 93: 18–20.

    PubMed  CAS  Google Scholar 

  286. Huttunen MO, Harkonen M, Niskanen P, Leino T, Ylikahri R. Plasma testosterone concentrations in alcoholics. J Stud Alcohol 1976; 37: 1165–1177.

    PubMed  CAS  Google Scholar 

  287. Fabre LF Jr, Howard PY, Farmer RW. Endocrine abnormalities in male alcoholic subjects. Tex Med 1972; 68: 88–93.

    PubMed  Google Scholar 

  288. Cornely CM, Schade RR, Van Thiel DH, Gavaler JS. Chronic advanced liver disease and impotence: cause and effect? Hepatology 1984; 4: 1227–1230.

    PubMed  CAS  Google Scholar 

  289. Farnsworth WE, Cavanaugh AH, Brown JR, Alvarez I, Lewandowski LM. Factors underlying infertility in the alcoholic. Arch Androl 1978; 1: 193–195.

    PubMed  CAS  Google Scholar 

  290. Gumus B, Yigitoglu MR, Lekili M, Uyanik BS, Muezzinoglu T, Buyuksu C. Effect of long-term alcohol abuse on male sexual function and serum gonadal hormone levels. Int Urol Nephrol 1998; 30: 755–759.

    Article  PubMed  CAS  Google Scholar 

  291. Simionescu L, Oprescu M, Protici M, Dimitriu V. The hormonal pattern in alcoholic disease. I. Luteinizing hormone (LH), follicle-stimulating hormone (FSH) and testosterone. Endocrinologie 1977; 15: 45–49.

    PubMed  CAS  Google Scholar 

  292. Gordon GG, Southren AL, Lieber CS. Hypogonadism and feminization in the male: a triple effect of alcohol. Alcohol Clin Exp Res 1979; 3: 210–212.

    PubMed  CAS  Google Scholar 

  293. Lindholm J, Fabricius-Bjerre N, Bahnsen M, Boiesen P, Hagen C, Christensen T. Sex steroids and sex-hormone binding globulin in males with chronic alcoholism. Eur J Clin Invest 1978; 8: 273–276.

    PubMed  CAS  Google Scholar 

  294. Gordon GG, Vittek J, Ho R, Rosenthal WS, Southren AL, Lieber CS. Effect of chronic alcohol use on hepatic testosterone 5-alpha-A-ring reductase in the baboon and in the human being. Gastroenterology 1979; 77: 110–114.

    PubMed  CAS  Google Scholar 

  295. Ylikorkala O, Stenman UH, Halmesmaki E. Testosterone, androstenedione, dehydroepiandrosterone sulfate, and sex-hormone-binding globulin in pregnant alcohol abusers. Obstet Gynecol 1988; 71: 731–735.

    PubMed  CAS  Google Scholar 

  296. Van Thiel DH, Gavaler JS, Lester R, Loriaux DL, Braunstein GD. Plasma estrone, prolactin, neurophysin, and sex steroid-binding globulin in chronic alcoholic men. Metabolism 1975; 24: 1015–1019.

    Article  PubMed  Google Scholar 

  297. McClain CJ, Van Thiel DH, Parker S, Badzin LK, Gilbert H. Alterations in zinc, vitamin A, and retinol-binding protein in chronic alcoholics: a possible mechanism for night blindness and hypogonadism. Alcohol Clin Exp Res 1979; 3: 135–141.

    PubMed  CAS  Google Scholar 

  298. Cicero TJ, Bell RD, Meyer ER, Badger TM. Ethanol and acetaldehyde directly inhibit testicular steroidogenesis. J Pharmacol Exp Ther 1980; 213: 228–233.

    PubMed  CAS  Google Scholar 

  299. Brzek A. Alcohol and male fertility (preliminary report). Andrologia 1987; 19: 32–36.

    Article  PubMed  CAS  Google Scholar 

  300. Nakagawa S, Watanabe H, Ohe H, Nakao M. Sexual behavior in Japanese males relating to area occupation, smoking, drinking and eating habits. Andrologia 1990; 22: 21–28.

    Article  PubMed  CAS  Google Scholar 

  301. Condra M, Morales A, Owen JA, Surridge DH, Fenemore J. Prevalence and significance of tobacco smoking in impotence. Urology 1986; 27: 495–498.

    Article  PubMed  CAS  Google Scholar 

  302. Nicolosi A, Moreira ED Jr, Shirai M, Bin Mohd Tambi MI, Glasser DB. Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology 2003; 61: 201–206.

    Article  PubMed  Google Scholar 

  303. Shiri R, Koskimaki J, Hakama M, et al. Effect of life-style factors on incidence of erectile dysfunction. Int J Impot Res 2004; 16: 389–394.

    Article  PubMed  CAS  Google Scholar 

  304. Rosen MP, Greenfield AJ, Walker TG, et al. Cigarette smoking: an independent risk factor for atherosclerosis in the hypogastric-cavernous arterial bed of men with arteriogenic impotence. J Urol 1991; 145: 759–763.

    PubMed  CAS  Google Scholar 

  305. Mersdorf A, Goldsmith PC, Diederichs W, et al. Ultrastructural changes in impotent penile tissue: a comparison of 65 patients. J Urol 1991; 145: 749–758.

    PubMed  CAS  Google Scholar 

  306. Glina S, Reichelt AC, Leao PP, Dos Reis JM. Impact of cigarette smoking on papaverine-induced erection. J Urol 1988; 140: 523–524.

    PubMed  CAS  Google Scholar 

  307. Tsitouras PD, Martin CE, Harman SM. Relationship of serum testosterone to sexual activity in healthy elderly men. J Gerontol 1982; 37: 288–293.

    PubMed  CAS  Google Scholar 

  308. Deslypere JP, Vermeulen A. Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. J Clin Endocrinol Metab 1984; 59: 955–962.

    PubMed  CAS  Google Scholar 

  309. Handelsman DJ, Conway AJ, Boylan LM, Turtle JR. Testicular function in potential sperm donors: normal ranges and the effects of smoking and varicocele. Int J Androl 1984; 7: 369–382.

    Article  PubMed  CAS  Google Scholar 

  310. Barrett-Conner E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 1988; 78: 539–545.

    Google Scholar 

  311. Evans HJ, Fletcher J, Torrance M, Hargreave TB. Sperm abnormalities and cigarette smoking. Lancet 1981; 1: 627–629.

    Article  PubMed  CAS  Google Scholar 

  312. Stillman RJ, Rosenberg MJ, Sachs BP. Smoking and reproduction. Fertil Steril 1986; 46: 545–566.

    PubMed  CAS  Google Scholar 

  313. Vine MF, Margolin BH, Morrison HI, Hulka BS. Cigarette smoking and sperm density: a meta-analysis. Fertil Steril 1994; 61: 35–43.

    PubMed  CAS  Google Scholar 

  314. Griffin M. Coffee Consumption in the United States. Coffee Research Institute 2006. Available from: http://coffeetea.about.com/gi/dynamic/offsite.htm?zi=1/XJ&sdn=coffeetea&zu=http%3A%2F%2Fwww.coffeeresearch.org%2Fmarket%2Fmarketintro.htm.

  315. Caffeine monograph. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  316. Smith BD, Davidson RA, Green RL. Effects of caffeine and gender on physiology and performance: further tests of a biobehavioral model. Physiol Behav 1993; 54: 415–422.

    Article  PubMed  CAS  Google Scholar 

  317. Kongkanand A. Prevalence of erectile dysfunction in Thailand. Thai Erectile Dysfunction Epidemiological Study Group. Int J Androl 2000; 23(Suppl 2): 77–80.

    Article  PubMed  Google Scholar 

  318. Shaeer KZ, Osegbe DN, Siddiqui SH, Razzaque A, Glasser DB, Jaguste V. Prevalence of erectile dysfunction and its correlates among men attending primary care clinics in three countries: Pakistan, Egypt, and Nigeria. Int J Impot Res 2003; 15(Suppl 1): S8–S14.

    Article  PubMed  Google Scholar 

  319. Cameron OG, Modell JG, Hariharan M. Caffeine and human cerebral blood flow: a positron emission tomography study. Life Sci 1990; 47: 1141–1146.

    Article  PubMed  CAS  Google Scholar 

  320. Karaki H, Ahn HY, Urakawa N. Caffeine-induced contraction in vascular smooth muscle. Arch Int Pharmacodyn Ther 1987; 285: 60–71.

    PubMed  CAS  Google Scholar 

  321. Takahashi Y, Ishii N, Aboseif SR, Benard F, Lue TF, Tanagho EA. Effects of adenosine on canine penile erection. J Urol 1990; 143: 305A.

    Google Scholar 

  322. Cicero TJ, Bell RD, Wiest WG, Allison JH, Polakoski K, Robins E. Function of the male sex organs in heroin and methadone users. N Engl J Med 1975; 292: 882–887.

    Article  PubMed  CAS  Google Scholar 

  323. Mirin SM, Meyer RE, Mendelson JH, Ellingboe J. Opiate use and sexual function. Am J Psychiatry 1980; 137: 909–915.

    PubMed  CAS  Google Scholar 

  324. Llorens C, Martres MP, Baudry M, Schwartz JC. Hypersensitivity to noradrenaline in cortex after chronic morphine: relevance to tolerance and dependence. Nature 1978; 274: 603–605.

    Article  PubMed  CAS  Google Scholar 

  325. Smith DE, Moser C, Wesson DR, et al. A clinical guide to the diagnosis and treatment of heroin-related sexual dysfunction. J Psychoactive Drugs 1982; 14: 91–99.

    PubMed  CAS  Google Scholar 

  326. Gay GR, Newmeyer JA, Perry M, Johnson G, Kurland M. Love and Haight: the sensuous hippie revisited. Drug/sex practices in San Francisco, 1980-81. J Psychoactive Drugs 1982; 14: 111–123.

    PubMed  CAS  Google Scholar 

  327. Gilbeau PM, Almirez RG, Holaday JW, Smith CG. The role of endogenous opioid peptides in the control of androgen levels in the male nonhuman primate. J Androl 1984; 5: 339–342.

    PubMed  CAS  Google Scholar 

  328. Delitala G, Giusti M, Mazzocchi G, Granziera L, Tarditi W, Giordano G. Participation of endogenous opiates in regulation of the hypothalamic-pituitary-testicular axis in normal men. J Clin Endocrinol Metab 1983; 57: 1277–1281.

    PubMed  CAS  Google Scholar 

  329. Beeley L. Drug-induced sexual dysfunction and infertility. Adverse Drug React Acute Poisoning Rev 1984; 3: 23–42.

    PubMed  CAS  Google Scholar 

  330. Cohen RA, Coffman JD. Effect of morphine on limb capacitance and resistance vessels. Clin Sci (Lond) 1981; 60: 5–9.

    CAS  Google Scholar 

  331. Flaim SF, Zelis R, Eisele JH. Differential effects of morphine on forearm blood flow: attenuation of sympathetic control of the cutaneous circulation. Clin Pharmacol Ther 1978; 23: 542–546.

    PubMed  CAS  Google Scholar 

  332. Halikas J, Weller R, Morse C. Effects of regular marijuana use on sexual performance. J Psychoactive Drugs 1982; 14: 59–70.

    PubMed  CAS  Google Scholar 

  333. Koff WC. Marijuana and sexual activity. J Sex Res 1974; 10: 194–204.

    Article  PubMed  CAS  Google Scholar 

  334. Mendelson JH, Kuehnle J, Ellingboe J, Babor TF. Plasma testosterone levels before, during and after chronic marihuana smoking. N Engl J Med 1974; 291: 1051–1055.

    Article  PubMed  CAS  Google Scholar 

  335. Schaefer CF, Gunn CG, Dubowski KM. Letter: Normal plasma testosterone concentrations after marihuana smoking. N Engl J Med 1975; 292: 867–868.

    PubMed  CAS  Google Scholar 

  336. Cushman P Jr. Plasma testosterone levels in healthy male marijuana smokers. Am J Drug Alcohol Abuse 1975; 2: 269–275.

    PubMed  CAS  Google Scholar 

  337. Block RI, Farinpour R, Schlechte JA. Effects of chronic marijuana use on testosterone, luteinizing hormone, follicle stimulating hormone, prolactin and cortisol in men and women. Drug Alcohol Depend 1991; 28: 121–128.

    Article  PubMed  CAS  Google Scholar 

  338. Cocaine monograph. In: Clinical Pharmacology: Gold Standard, 2005.

    Google Scholar 

  339. Cocores JA, Miller NS, Pottash AC, Gold MS. Sexual dysfunction in abusers of cocaine and alcohol. Am J Drug Alcohol Abuse 1988; 14: 169–173.

    PubMed  CAS  Google Scholar 

  340. Cocores JA, Dackis CA, Gold MS. Sexual dysfunction secondary to cocaine abuse in two patients. J Clin Psychiatry 1986; 47: 384–385.

    PubMed  CAS  Google Scholar 

  341. Altman AL, Seftel AD, Brown SL, Hampel N. Cocaine associated priapism. J Urol 1999; 161: 1817–1818.

    Article  PubMed  CAS  Google Scholar 

  342. Munarriz R, Hwang J, Goldstein I, Traish AM, Kim NN. Cocaine and ephedrine-induced priapism: case reports and investigation of potential adrenergic mechanisms. Urology 2003; 62: 187–192.

    Article  PubMed  Google Scholar 

Download references

Authors
  1. Benjamin K. Yang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Craig F. Donatucci MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Yang, B.K., Donatucci, C.F. (2006). Drugs That Affect Male Sexual Function. In: Male Sexual Function. Current Clinical Urology. Humana Press. https://doi.org/10.1007/978-1-59745-155-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-155-0_8

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-747-1

  • Online ISBN: 978-1-59745-155-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation